NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Tarsus reported first quarter results with a net loss, offset by license fee and collaboration revenue. TP-03 met all endpoints in the Saturn-2 Phase 3 trial.
Tarsus Pharmaceuticals reported a net loss of $20.2 million for the first quarter of 2022, compared to a net income of $10.4 million for the same period in 2021. The company's TP-03 product met all endpoints in the Saturn-2 Phase 3 trial, and the company anticipates NDA submission in the second half of this year. Cash runway is expected into at least 2026.
- TP-03 met primary and all secondary endpoints in Saturn-2 Phase 3 trial.
- Advanced TP-05 in the Callisto Phase 1b trial, with data expected in the second half of 2022.
- Cash runway expected into at least 2026 with $175 million in cash as of March 31, 2022.
- First quarter net loss for 2022 was $20.2 million.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$539K
Forward guidance
Tarsus anticipates several milestones in 2022, including NDA submission for TP-03 and Phase 2a initiation for TP-05.
Tailwinds
- TP-03 Topline Pivotal Data (Saturn-2) for Demodex blepharitis in H1 2022
- TP-03 NDA Submission for Demodex blepharitis in H2 2022
- TP-05 Phase 1b Data (Callisto) for Lyme disease prevention in H2 2022
- TP-03 Initiate Phase 3 trial in China for Demodex blepharitis in H2 2022
- TP-04 Initiate Phase 2 (Galatea) for Rosacea in H2 2022
Headwinds
- Incurred significant losses and negative cash flows from operations since inception
- May need to obtain additional funding to complete the development and any commercialization of its product candidates
- Heavily dependent on the success of its lead product candidate, TP-03 for the treatment of Demodex blepharitis
- COVID-19 pandemic may affect Tarsus’ ability to initiate and complete preclinical studies and clinical trials
- Sizes of the market opportunity for Tarsus’ product candidates have not been established with precision and may be smaller than estimated
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro